Insulet — Nov 6, 2025 release

Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. 10 INSULET CORPORATION NON-GAAP RECONCILIATIONS (UNAUDITED) CONTINUED REVENUE GUIDANCE Year Ending December 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 26% - 27% —% 26% - 27% International Omnipod 43% - 44% 5% 38% - 39% Total Omnipod 30% - 31% 1% 29% - 30% Drug Delivery (15)% - (10)% —% (15)% - (10)% Total 29% - 30% 1% 28% - 29% Three Months Ended December 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 24% - 27% —% 24% - 27% International Omnipod 47% - 50% 10% 37% - 40% Total Omnipod 30% - 33% 3% 27% - 30% Drug Delivery (95)% - (85)% —% (95)% - (85)% Total 27% - 30% 2% 25% - 28% 11